Multiple Sclerosis and Subcutaneous Panniculitis-like T Cell Lymphoma with Hemophagocytic Syndrome: The Role of Treatment Sequencing in the Pathogenetic Mechanism
Authors:
- Assunta TrinchilloATAssunta Trinchillo
- Antonio CarotenutoACAntonio Carotenuto
- Antonio Luca SpieziaASAntonio Luca Spiezia
- Daniele CaliendoDCDaniele Caliendo
- Alessandro SeverinoASAlessandro Severino
- Cristina Di MonacoCMCristina Di Monaco
- Carmine IacovazzoCICarmine Iacovazzo
- Giuseppe ServilloGSGiuseppe Servillo
- Vincenzo Brescia MorraVMVincenzo Brescia Morra
- Roberta LanzilloRLRoberta Lanzillo
Open Access
Abstract
Introduction: Although panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) have been described as complications following immunosuppressive treatments, there are no reported cases of concomitant SPTCL/HSP and multiple sclerosis (MS). Materials and Methods: We describe the case of a patient affected by an aggressive phenotype of relapsing remitting MS, characterized by consecutive severe relapses with no complete remission. He developed panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) after receiving multiple immunosuppressive treatments in sequence. Despite the aggressive nature of these complications, the patient responded well to a combination of Gemcitabine and Cisplatin. Discussion and Conclusions: With this case, we suggest that physicians always consider blood diseases as possible MS therapy complications, especially in the sequencing setting, and also consider uncommon treatments in those with autoimmune predispositions.Keywords
This publication has 38 references indexed in Scilit:
- Subcutaneous panniculitis-like T-cell lymphoma in two unrelated individuals with BENTA diseaseClinical Immunology, 2023
- Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literatureNeurological Sciences, 2023
- Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapyBest Practice & Research Clinical Rheumatology, 2020
- Lymphoma in the setting of autoimmune diseases: A review of association and mechanismsCritical Reviews in Oncology/Hematology, 2020
- Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patientsJournal of Neurology, 2018
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of AlemtuzumabJAMA Neurology, 2017
- Subcutaneous panniculitis–like T-cell lymphoma after rituximabJournal of the American Academy of Dermatology, 2012
- Primary central nervous system lymphoma in a patient treated with natalizumabAnnals of Neurology, 2009
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005
- Aggressive cutaneous T-cell lymphomas after TNFα blockadeJournal of the American Academy of Dermatology, 2004